Showing 9951-9960 of 20329 results for "".
- Protein Timing for Enhanced Athletic Performance: Insights from a Casein Timing Trialhttps://reachmd.com/news/protein-athletic-performance-casein-timing/2484971/A casein timing trial found that both pre-sleep and immediate post-exercise casein (≈30 g) improved anaerobic performance in highly trained soccer players with no timing strategy clearly superi
- Rapid Adoption of SPRINT PNS Systems: Milestones and Clinical Impactshttps://reachmd.com/news/rapid-adoption-of-sprint-pns-systems-milestones-and-clinical-impacts/2484937/SPR Therapeutics announced that the SPR Therapeutics SPRINT PNS system has reached its 50,000th implant, re
- Revolutionizing Renal Replacement: Impact of the FDA's Breakthrough Device Designation for Holly Implantable Kidneyhttps://reachmd.com/news/revolutionizing-renal-replacement-impact-of-the-fdas-breakthrough-device-designation-for-holly-implantable-kidney/2484940/Nephrodite’s Holly implantable kidney
- Unraveling the Impact of GDF3 Signaling in Age-Related Inflammationhttps://reachmd.com/news/unraveling-the-impact-of-gdf3-signaling-in-age-related-inflammation/2484949/University of Minnesota researchers show that macrophage-derived GDF3 sustains low-grade inflammation in older adults and increases vulnerability to infection, linking aged immune cell
- Innovation in Pancreatic Cancer Care: UT Health San Antonio's Breakthrough with Radiofrequency Ablationhttps://reachmd.com/news/innovation-in-pancreatic-cancer-care-ut-health-san-antonios-breakthrough-with-radiofrequency-ablation/2484938/UT Health San Antonio performed the first regional endoscopic radiofrequency ablation (RFA) for an inoperable pancreatic cancer pat
- Evaluating Nerinetide in Acute Ischemic Stroke: Insights from Latest Meta-Analysishttps://reachmd.com/news/evaluating-nerinetide-in-acute-ischemic-stroke-insights-from-latest-meta-analysis/2484951/Nerinetide, delivered intravenously as a neuroprotective adjunct during endovascular thrombectomy (EVT) when IV thrombolysis is withheld, does not improve 90‑day functional outcomes.
- Isotretinoin Slows Growth Rate in Teens, But Final Height Unchangedhttps://reachmd.com/news/isotretinoin-slows-growth-rate-in-teens-but-final-height-unchanged/2484962/Adolescents treated with isotretinoin for acne may experience temporary reductions in height velocity, but the medication does not appear to impact final adult height, according to a new retrospective cohort study published in the
- Unlocking the Immune Code: Advances in Lichen Planus Pathogenesis and Emerging Therapieshttps://reachmd.com/news/unlocking-the-immune-code-advances-in-lichen-planus-pathogenesis-and-emerging-therapies/2484954/Once considered a relatively obscure dermatologic condition, lichen planus (LP) is gaining renewed scientific interest thanks to
- Most Insurers Cover Botulinum Toxin for Axillary Hyperhidrosis: Analysishttps://reachmd.com/news/most-insurers-cover-botulinum-toxin-for-axillary-hyperhidrosis-analysis/2484933/A new cross-sectional study published in the Journal of Drugs in Dermatology finds that while botulinum toxin is broadly covered by private insurers for the treatment of primary axillary hyperhidrosis, access barriers due to
- Evaluating Targeted Therapies for Inflammatory Skin Diseases: A Focus on Baricitinib in Lichen Planushttps://reachmd.com/news/evaluating-targeted-therapies-for-inflammatory-skin-diseases-a-focus-on-baricitinib-in-lichen-planus/2484952/Mayo Clinic investigators show that baricitinib produces rapid clinical benefit in liche